Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. clinical trials
Acquired by 3SBio Inc., Mar 31, 2016 · source ↗
The registry lists 58 studies whose lead sponsor is Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. 21 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 9, 2026.
Before and after it joined 3SBio Inc.
- First submitted before Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- 0
- First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- 58
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.58 studies
Something wrong with this grouping? Tell us on the 3SBio Inc. page.
Studies
Recruiting first, then most recently updated. Showing 50 of 58. List all 58 → · All 3SBio Inc. studies →
- Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD)RecruitingNCT07767253Phase 3
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UCRecruitingNCT07507513Phase 2
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering TreatmentNot yet recruitingNCT07708181Phase 2
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- A Phase I Study of SSGJ-716 in Healthy Adults and Participants With Moderate-to-Severe Atopic DermatitisRecruitingNCT07693738Phase 1
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- A Study to Evaluate the Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)Not yet recruitingNCT07349329Phase 3
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- Efficacy and Safety Study of 610 in Patients With Severe AsthmaRecruitingNCT06323213Phase 3
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS)RecruitingNCT07261644Phase 3
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLERecruitingNCT07185269Phase 1/2
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic DermatitisRecruitingNCT07042126Phase 3
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseRecruitingNCT07039669Phase 3
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- Evaluation of 627 in Healthy Adult SubjectsNot yet recruitingNCT07065136Phase 1
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- A Study of Two Different Formulations of 611 in Healthy Adult Subjects in ChinaNot yet recruitingNCT07042113Phase 1
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)RecruitingNCT06222671Phase 2
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer PatientsRecruitingNCT06522828Phase 2
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant TumorsRecruitingNCT06390774Phase 1
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer PatientsRecruitingNCT06493760Phase 2
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC PatientsRecruitingNCT06412471Phase 2
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC PatientsRecruitingNCT06361927Phase 2
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsONot yet recruitingNCT06299982Phase 3
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute GoutNot yet recruitingNCT06169891Phase 3
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- The MAD Study of SSGJ-613 in Healthy SubjectsNot yet recruitingNCT05966701Phase 1
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic DermatitisCompletedNCT06554847Phase 3
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- Evaluation of 626 in Healthy Adult SubjectsCompletedNCT06674525Phase 1
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic DermatitisCompletedNCT06324812Phase 1/2
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- A Phase IIb Study of 610 in Participants With Severe Eosinophilic AsthmaActive, not recruitingNCT06680947Phase 2
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic DermatitisCompletedNCT06173284Phase 3
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- A Phase III Study for 601 Versus Ranibizumab in Patients With Vision LossCompletedNCT05520177Phase 3
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal PolypsActive, not recruitingNCT06639295Phase 3
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- Evaluation of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary DiseaseCompletedNCT06099652Phase 2
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- 601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)CompletedNCT04667910Phase 2
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- 601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)CompletedNCT04667897Phase 2
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque PsoriasisCompletedNCT05536726Phase 3
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS)Active, not recruitingNCT06242652Phase 2
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.Active, not recruitingNCT06270225Phase 2
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- Phase I Clinical Study to Evaluate the Safety and Efficacy of SSGJ-706 Monotherapy for Patients With Advanced Solid TumorsStatus unknownNCT06533605Phase 1
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic DermatitisCompletedNCT05544591Phase 2
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal PolypsActive, not recruitingNCT05865496Phase 2
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- Evaluation of 611 in Chinese Adult Patients With Moderate-to-Severe Atopic DermatitisCompletedNCT05641558Phase 1/2
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy VolunteersCompletedNCT04527718Phase 1
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque PsoriasisStatus unknownNCT05604898Phase 2
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute GoutStatus unknownNCT05588908Phase 1/2
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic AsthmaStatus unknownNCT05584306Phase 1
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- A Phase II Study of 610 in Participants With Severe Eosinophilic AsthmaStatus unknownNCT05528679Phase 2
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic SarcomaStatus unknownNCT05193214Phase 2
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid TumorsStatus unknownNCT05145179Phase 1
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue SarcomaStatus unknownNCT05138146Phase 2
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody InjectionStatus unknownNCT05027373Phase 1
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal CancerStatus unknownNCT04466254Phase 2
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- 601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)Status unknownNCT04922151Phase 2
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.
- Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-5 Humanized Monoclonal Antibody InjectionStatus unknownNCT04445038Phase 1
Sponsor listed in the registry: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc.